Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.

Cancer immunology research - 1 Oct 2018

Adeegbe Dennis O, Liu Shengwu, Hattersley Maureen M, Bowden Michaela, Zhou Chensheng W, Li Shuai, Vlahos Raven, Grondine Michael, Dolgalev Igor, Ivanova Elena V, Quinn Max M, Gao Peng, Hammerman Peter S, Bradner James E, Diehl J Alan, Rustgi Anil K, Bass Adam J, Tsirigos Aristotelis, Freeman Gordon J, Chen Huawei, Wong Kwok-Kin

Abstract excerpt

KRAS mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render KRAS-mutant tumors even more resistant to existing therapies. Contributing to the refractoriness of KRAS-mutant tumors are immunosuppressive mechanisms, such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to Azepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytokines

Share to Mice, Nude

Share to Programmed Cell Death 1 Receptor

Share to Proto-Oncogene Proteins p21(ras)

Share to T-Lymphocytes

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 30087114
DOI: 10.1158/2326-6066.CIR-18-0077
PMCID: PMC6170698

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.PMID 30087114Read ↗

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung CancerSemantic proximity Read ↗

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.Semantic proximity Read ↗

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung CancerSemantic proximity Read ↗

PD-1/PD-L1 Axis in Lung Cancer.Semantic proximity Read ↗

Novel <i>Kras</i> -mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burdenSemantic proximity Read ↗

The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsSemantic proximity Read ↗

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?Semantic proximity Read ↗

BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.Semantic proximity Read ↗

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read ↗

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomasSemantic proximity Read ↗

Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.